PBH Prestige Consumer Healthcare Inc.

$49.76 +1.41%

Data as of Nov 2, 2026 close

Healthcare · Pharmaceutical Preparations

Prestige Consumer Healthcare Inc. (PBH) is a healthcare company in the Pharmaceutical Preparations industry, with a market capitalization of $2.4 billion. Shares last traded at $49.76, 30.0% below their 52-week high. Over the past year the stock is down 17.4%. PBH trades at a price-to-earnings ratio of 13.70, below the Pharmaceutical Preparations median of 17.04. Net profit margin is 15.6%, above the peer median of -7.6%. Revenue declined 4.3% year over year.

Market Cap

$2.4B

Shares Out

47.4M

EPS (TTM)

$3.57

P/E (TTM)*

13.70

P/S Ratio

2.13

P/B Ratio

1.23

Dividend / Share

—

Dividend Yield

—

52-Week High

$71.07

52-Week Low

$42.89

Volume (venue)

29,050

Avg Vol (3m, venue)

30,984.778

* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.

Performance

+3.30%

+9.92%

-4.22%

-10.00%

YTD

-19.33%

-17.42%

Chart

Full chart →

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)

57.17

SMA (50)

$48.51

SMA (200)

$54.01

Price vs SMA50

+2.58%

Price vs SMA200

-7.87%

ATR (14)

$1.81

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue

$1.1B

Net Income

$172M

Gross Margin

53.5%

Operating Margin

26.3%

Net Margin

15.6%

Return on Equity

9.0%

Return on Assets

3.8%

Current Ratio

3.23

Debt / Equity

1.05

Revenue Growth (YoY)

-4.3%

Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-06-30. Source: SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

Period	EPS (diluted)	Reported
Q1 2027	$0.61	2026-08-06
Q4 2026 (derived)	$1.13	2026-05-14
FY 2026	$3.91	2026-05-14
Q3 2026	$0.97	2026-02-05
Q2 2026	$0.86	2025-11-06
Q1 2026	$0.95	2025-08-07

Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.

Full earnings history →

Pharmaceutical Preparations peers

PBH vs 14 industry peers (Pharmaceutical Preparations), by market cap. Data as of Nov 2, 2026 close

P/E vs peers

13.70 / 17.04 med

-20% discount

P/S vs peers

2.13 / 7.81 med

-73% discount

Net margin vs peers

15.6% / -7.6% med

above median

1–14 of 14


LLY	Lilly (Eli)	$1.33T	48.13	15.35	31.9%	-0.28%
JNJ	Johnson & Johnson	$652.2B	40.52	6.57	16.2%	-0.82%
ONC	Beone Medicines Ltd.	$533.8B	814.05	87.09	10.7%	-2.48%
ABBV	AbbVie	$510.3B	80.87	7.93	9.8%	-2.05%
MRK	Merck	$366.4B	115.46	5.50	4.8%	-0.22%
ABT	Abbott Laboratories	$192.1B	30.61	4.26	13.9%	+3.81%
PFE	Pfizer	$175.0B	40.41	2.75	6.8%	+0.69%
VRTX	Vertex Pharmaceuticals	$144.5B	32.80	11.48	35.0%	+1.96%
BMY	Bristol Myers Squibb	$128.8B	13.94	2.58	18.5%	+0.90%
REGN	Regeneron Pharmaceuticals	$99.4B	20.64	5.89	28.5%	+3.63%
TEVA	Teva Pharmaceutical Industries Ltd	$47.4B	67.14	2.74	4.1%	-3.35%
ZTS	Zoetis	$34.4B	13.14	3.61	27.5%	+4.35%
RPRX	Royalty Pharma Plc	$29.6B	36.35	11.68	32.1%	-0.98%
ROIV	Roivant Sciences Ltd.	$25.9B	—	3441.87	—	-2.76%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.